Updated Phase1B Results for Talquetamab in Combination with Daratumumab Presented at EHA 2022

Dr. Dr. Niels W.C.J. van de Donk Discusses Updated Phase1B Results for Talquetamab in Combination with Daratumumab for the Treatment of RRMM Patients

Abstract Title:

Novel Combination Immunotherapy for the Treatment of Relapsed/Refractory Multiple Myeloma: Updated Phase1B Results for Talquetamab (A GPRC5D x CD3 Bispecific Antibody) in Combination with Daratumumab

What is the purpose of this trial? 

Talquetamab (tal; JNJ-64407564) is a first-in-class, bispecific IgG4 antibody that binds both to G protein-coupled receptor family C group 5 member D (GPRC5D), a receptor highly expressed on malignant plasma cells but with limited expression in healthy tissue, and CD3 to mediate T-cell–activated lysis of GPRC5D+ multiple myeloma (MM) cells. Daratumumab (dara) is an anti-CD38 mAb with direct on-tumor and immunomodulatory actions. Initial clinical results from the phase 1b multicohort TRIMM-2 study identified the recommended phase 2 doses (RP2Ds) and support the combination of tal plus dara for the treatment of RRMM, with manageable safety, no overlapping toxicities, and promising efficacy.

Updated results for both RP2Ds of tal plus dara in TRIMM-2 with additional patients and longer follow-up are reported here. 

In this video:

Dr. Niels W.C.J. van de Donk (VU University Medical Center—Amsterdam, Netherlands) reports on updated Phase1B results for talquetamab in combination with daratumumab for the treatment of relapsed/refractory multiple myeloma (RRMM) patients.   

Conclusion:

Longer follow-up with additional patients shows comparable efficacy and safety across both RP2Ds, with no new safety signals, strengthening the benefit-risk profile of tal + dara as a novel immunotherapy-based approach for heavily pretreated RRMM patients.